HWHG(SH:600079) Shang Hai Zheng Quan Bao·2025-11-21 19:52Core Viewpoint - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Dexmethylphenidate Hydrochloride Capsules from the National Medical Products Administration, marking a significant step in the drug's approval process [1][2]. Group 1: Drug Registration Details - The drug name is Dexmethylphenidate Hydrochloride Capsules, classified as a Class 3 chemical drug [1]. - The application is for domestic production and is specifically aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 and above [2]. - The acceptance of the application indicates that the drug is now entering the review phase, which could enhance the company's product line and market competitiveness if approved [2]. Group 2: Research and Development Investment - The total research and development investment for this project has reached approximately 90 million RMB [2]. - Currently, there are no similar products approved for sale in the domestic market, indicating a potential first-mover advantage for the company [2]. Group 3: Future Steps and Market Impact - The company plans to actively promote subsequent related work following the acceptance of the application [2]. - Successful approval could significantly enrich the company's product offerings and improve its competitive position in the pharmaceutical market [2].